Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Laboratory Corporation Of America Holdings (LH)
NYSE:LH
Laboratory (LH) Stock Price & Analysis
1,002 Followers
LH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$191.97 - $234.09
Previous Close$209.49
Volume470.54K
Average Volume (3M)667.00K
Market Cap
$17.66B
Enterprise Value$21.49B
Total Cash (Recent Filing)$99.30M
Total Debt (Recent Filing)$3.93B
Price to Earnings (P/E)42.3
Beta0.91
Next Earnings
Aug 01, 2024EPS Estimate
$3.78Last Dividend Ex-Date
May 24, 2024Dividend Yield1.39%
Share Statistics
EPS (TTM)4.95
Shares Outstanding84,293,628
10 Day Avg. Volume695,424
30 Day Avg. Volume667,000
Standard Deviation0.08
R-Squared0.41
Alpha-0.00554
Financial Highlights & Ratios
Price to Book (P/B)-10.46
Price to Sales (P/S)5.70
Price to Cash Flow (P/CF)-145.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.75
Enterprise Value/Gross Profit6.39
Enterprise Value/Ebitda14.48
Forecast
1Y Price Target
$247.25Price Target Upside17.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Laboratory News
PremiumCompany Announcements
Labcorp Q2 2024 Financial Results and Conference Call Announcement
PremiumCompany Announcements
Laboratory Holdings Executives Present at Growth Stock Conference
PremiumCompany Announcements
Laboratory Corp to Present at Annual Growth Stock Conference
Bulls Say, Bears Say
Bulls Say
Biotech FundingOptimistic that LH shares are positioned to gain positive momentum as improved biotech funding translates to an uptick in bookings.
Diagnostics PerformanceLH posted strong results in its core Diagnostics business, aided by broader healthcare utilization strength that translated to segment-level beats on volumes, revenues, and earnings.
Market Share GainsSolid base diagnostics trends continue to be a highlight, supported by strong underlying demand and market share gains as LH continues to execute on its hospital lab acquisition strategy.
Bears Say
Acquisition ImpactThe stock was down -4% due to the announced winning bid for select assets of Invitae, a medical genetics company currently undergoing bankruptcy.
Regulatory ConcernsWhile management supports FDA oversight for LDTs, it is fundamentally against the final regulation.
Segment PerformanceWeakness in Early Development (even though it's only 7% of enterprise-level revenues), which prompted management to reduce segment-level guidance, caused LH shares to soften post-release.
---
Ownership Overview
1.48% Insiders
29.97% Mutual Funds
25.97% Other Institutional Investors
42.59% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LH FAQ
What was Laboratory Corporation Of America Holdings’s price range in the past 12 months?
Laboratory Corporation Of America Holdings lowest stock price was $191.97 and its highest was $234.09 in the past 12 months.
What is Laboratory Corporation Of America Holdings’s market cap?
Currently, no data Available
When is Laboratory Corporation Of America Holdings’s upcoming earnings report date?
Laboratory Corporation Of America Holdings’s upcoming earnings report date is Aug 01, 2024 which is in 6 days.
How were Laboratory Corporation Of America Holdings’s earnings last quarter?
Laboratory Corporation Of America Holdings released its earnings results on Apr 25, 2024. The company reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.484 by $0.196.
Is Laboratory Corporation Of America Holdings overvalued?
According to Wall Street analysts Laboratory Corporation Of America Holdings’s price is currently Undervalued.
Does Laboratory Corporation Of America Holdings pay dividends?
Laboratory Corporation Of America Holdings pays a Quarterly dividend of $0.72 which represents an annual dividend yield of 1.39%. See more information on Laboratory Corporation Of America Holdings dividends here
What is Laboratory Corporation Of America Holdings’s EPS estimate?
Laboratory Corporation Of America Holdings’s EPS estimate is $3.78.
How many shares outstanding does Laboratory Corporation Of America Holdings have?
Laboratory Corporation Of America Holdings has 84,293,625 shares outstanding.
What happened to Laboratory Corporation Of America Holdings’s price movement after its last earnings report?
Laboratory Corporation Of America Holdings reported an EPS of $3.68 in its last earnings report, beating expectations of $3.484. Following the earnings report the stock price went down -4.614%.
Which hedge fund is a major shareholder of Laboratory Corporation Of America Holdings?
Among the largest hedge funds holding Laboratory Corporation Of America Holdings’s share is Diamond Hill Capital Management Inc. It holds Laboratory Corporation Of America Holdings’s shares valued at 340M.
---
Laboratory Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$247.25 (17.90% Upside)
$247.25 (17.90% Upside)
Blogger Sentiment
Bullish
LH Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 556.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 9.7%
Last 30 Days ▲ 9.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.93%
12-Months-Change
Fundamentals
Return on Equity
4.36%
Trailing 12-Months
Asset Growth
-18.16%
Trailing 12-Months
Company Description
Laboratory Corporation Of America Holdings
Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing. The Covance Drug Development segment involves in providing drug development solutions, to companies in the pharmaceutical and biotechnology industries. The company was founded in 1971 and is headquartered in Burlington, NC.
---
LH Company Deck
---
LH Earnings Call
Q1 2024
0:00 / 0:00
---
LH Revenue Breakdown
77.42% Dx
22.81% BLS
---
LH Stock 12 Month Forecast
Average Price Target
$247.25
▲(17.90% Upside)
Technical Analysis
Best Analysts Covering LH
1 Year
1 Year Success Rate
15/19 ratings generated profit
1 Year Average Return
+14.22%
reiterated a buy rating 11 days ago
Copying Erin Wright's trades and holding each position for 1 Year would result in 78.95% of your transactions generating a profit, with an average return of +14.22% per trade.
---